UBS launched its coverage of Sagimet Biosciences (NASDAQ:SGMT) with a buy recommendation and a $12 price target, calling the company an underappreciated player in the market for liver disorder, ...

The market expects Lowe's (LOW) to deliver a year-over-year decline in earnings on lower revenues when it reports results for the quarter ended October 2024. This widely-known consensus outlook is ...

T-mobile is a good buy opportunity due to its attractive bundling and customer-centric approach, ambitious plans supported by ...

Detroit-based coworking firm Bamboo plans to purchase and redevelop the former Urban Institute for Contemporary Arts building ...

Warren Buffett is one of the greatest and most respected investors of all time. Most investors would like to emulate ...

This is not a blog post about John Mayer doing something with Mk.gee, the ascendant phenom who played SNL last weekend and ...

Cloud networking startup Aviatrix Systems is offering up its flagship platform in a new consumption-based model option in the ...

The project, the largest to date from a Pennsylvania utility, will be part of it's default service and power up to 3,000 ...

Even if the company disappoints in the fiscal Q4 (whose earnings call will be on November 14) and runs the risk of this ...

(The company uses a slightly different metric for FCF called adjusted ... FCF has consistently and significantly been ...